Conference proceeding | Open Access

Alzheimer's and Parkinson's Diseases Face Common

Diane Stephenson [1*], Martha Brumfield [1], ..., Issam Zineh [2], ..., Walter Koroshetz [6], ..., Les Shaw [10], Johan Luthman

Keywords: Alzheimer's disease; Parkinson's disease; erapy development; Precompetitive consortium; Regulatory science

Introduction

CAMD and FDA: A decade a er the critical path initiative

It has been a decade since the U.S. Food and Drug Administration (FDA)published the Critical Path Initiative, articulating the need for cross-disciplinary collaboration to move science forward and expedite drug development [1]. Despite much progress, major challenges remain. Today, the Critical Path Institute (C-Path), founded in 2005, comprises eight consortia aimed at providing the resources, tools and infrastructure to increase the e ciency of the drug development process by focusing on indication-speci c areas [Alzheimer's disease, (AD), Parkinson's disease, (PD), multiple sclerosis, tuberculosis, polycystic kidney disease] or on broad areas like translational drug safety or patient-reported outcome measures. C-Path consortia bring

&LWDWLRQ LQIRUPDWLRQ IRU WKLV DUWLFOH $O]KHLPHU¶V DQG 3DUNLQVRQ¶V 'LVHDVH
LQ 7KHUDSHXWLF 'HYHORSPHQW 5ROH RI WKH 3UHFRPSHWLWLYH &RQVRUWLXP &RDO
GRL

development through the issuance of guidance that has applicability

9DQ 5RVVXP ,$ 9RV 6- %XUQV / .QRO '/ 6FKHOWHQV 3 HW DO ,QMXU\ PDUNHUV SUHGLFW WLPH Wi € `psULFW \pÀ 0 WeñÚ @Pà€ð0 WeñÚ @Pà€ð0 TÀPePà) T% 'LVHDVHV VHDH 4À`